Here are five things to know:
1. J&J is among the largest 10 companies in the world. On Friday, the company reported $328 billion market valuation.
2. The company’s products are inelastic, so there is more likelihood of generating consistent growth and cash-flow even if the economy takes a downturn or there is a recession. The company focuses on medical devices and pharmaceuticals in addition to consumer products that continue to be in demand.
3. The pharmaceutical company plans to submit 10 new drug applications through 2019 that have “blockbuster potential” according to the report. The company brought in 14 novel therapies with seven that have annual sales of $1 billion or more from 2009 to 2014.
4. Pricing power for J&J could stay strong as Congress will likely run into roadblocks trying to cap or control prescription drug pricing. The company can use the cash flow generated from “blockbuster” drugs for further internal research and acquisitions.
5. As the elderly population grows, demand for orthopedic medical devices such as hip and knee implants will be on the rise. There are also more people with insurance who can seek elective treatments.
6. J&J’s traditionally slower growth as a high volatility stock could impede its quest to become the first $1 trillion company but overtime it could push in that direction.
More articles on orthopedic devices:
Medtronic, SeaSpine, Zimmer Biomet & more: 1 key notes
Medical device makers pivot towards value-based care: 7 thoughts
Gregory Lucier drives NuVasive to be the best in spine space: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
